Psychedelics

Name: Psychedelics
Brand: Hodder & Stoughton
SKU: 9781399719681
Price: 39.99 NZD
Availability: InStock

The revolutionary drugs that could change your life – a guide from the expert

By Professor David Nutt

4.43

( 363 ratings, 45 reviews)

Summary

Psychedelics by Professor David Nutt explores the science and therapeutic potential of psychedelic substances. Nutt delves into their historical use, the neuroscientific underpinnings, and contemporary research addressing their applications in treating mental health disorders. It's an insightful and thorough examination of how psychedelics could revolutionise modern psychiatry.
Read More

Format: Paperback / softback

$39⁹⁹

OVERNIGHT DELIVERY

Found a better price? Request a price match

Psychedelics

$39⁹⁹

Book Hero Magic created this recommendation. While it's new and still learning, it may not be perfect - your feedback is welcome! IS THIS YOUR NEXT READ?

You might enjoy this book if you're fascinated by the science of psychedelics, curious about their potential therapeutic benefits, or interested in the history and culture surrounding these substances. It offers insightful perspectives and is written by an expert in the field, making complex concepts accessible and engaging.

Psychedelics

The definitive guide to psychedelics, science and our health by a world-renowned, leading authority, Professor David Nutt.

Description

We are on the cusp of a major revolution in psychiatric medicine and neuroscience. After fifty years of prohibition, criminalisation and fear, science is finally showing us that psychedelics are not dangerous or harmful. Instead, when used according to tested, safe and ethical guidelines, they are our most powerful newest treatment of mental health conditions, from depression, PTSD, and OCD to disordered eating and even addiction and chronic pain.

Professor David Nutt, one of the world's leading Neuropsychopharmacologists, has spent 15 years researching this field and it is his most significant body of work to date. In 2018, he co-founded the first academic psychedelic research centre - underpinned by his mission to provide evidence-based information for people everywhere. It revived interest in the understanding and use of this drug in its many forms, including MDMA, ayahuasca, magic mushrooms, LSD and ketamine. The results of this have been nothing short of ground-breaking for the future categorisation of drugs, but also for what we now know about brain mechanisms and our consciousness.

At a time where there is an enormous amount of noise around the benefits of psychedelics, Psychedelics contains the knowledge you need to know about a drug that is about to go mainstream, free from the hot air, direct from the expert.

Are you ready to change your mind?

Book Hero Magic summarised reviews for this book. While it's new and still learning, it may not be perfect - your feedback is welcome! HOW HAS THIS BEEN REVIEWED?

Psychedelics by Professor David Nutt is praised for its insightful and balanced exploration of the potential benefits and risks of psychedelic substances. Reviewers commend Nutt's accessible writing style and thorough scientific analysis, noting the book's ability to challenge preconceived notions while providing a well-rounded perspective on an often controversial topic.

Book Details

INFORMATION

ISBN: 9781399719681

Publisher: Hodder & Stoughton

Format: Paperback / softback

Date Published: 29 June 2023

Country: United Kingdom

Imprint: Yellow Kite

Audience: General / adult

DIMENSIONS

Spine width: 28.0mm

Width: 152.0mm

Height: 232.0mm

Weight: 420g

Pages: 336

Collections

Education & Reference Health & Wellness New at Book Hero Non-Fiction Professor David Nutt Science & Nature Self-Help & Personal Development

About the Author

David Nutt is Professor of Neuropsychopharmacology and director of the Neuropsychopharmacology Unit in the Division of Brain Sciences at Imperial College, London.

After completing his medical training at Guy's Hospital London, continuing in neurology to MRCP, he went on to his psychiatric training in Oxford, he continued there as a lecturer and then later as a Wellcome Senior Fellow in psychiatry. He then spent two years as Chief of the Section of Clinical Science in the National Institute of Alcohol Abuse and Alcoholism in NIH, Bethesda, USA. On returning to England in 1988 he set up the Psychopharmacology Unit in Bristol University, an interdisciplinary research grouping spanning the departments of Psychiatry and Pharmacology before moving to Imperial College London in December 2008 where he leads a similar group with a particular focus on brain imaging especially PET.

David is currently Chair of DrugScience (formally the Independent Scientific Committee on Drugs (ISCD) and President of the European Brain Council. previously he has been President of the European College of Neuropsychopharmacology (ECNP), the British Neuroscience Association (BNA) and the British Association of Psychopharmacology (BAP). In addition, he is a Fellow of the Royal Colleges of Physicians and of Psychiatrists and a Fellow of the Academy of Medical Sciences. He is also the UK Director of the European Certificate and Masters in Affective Disorders Courses and a member of the International Centre for Science in Drug Policy. He has edited the Journal of Psychopharmacology for over two decades and acts as the psychiatry drugs advisor to the British National Formulary.

Previously he has been a member and then Chair of the Advisory Committee on the Misuse of Drugs (ACMD - 1998-2009), a member of the HEFCE/NHS Senior Lecturer Selection Panel and of the MRC Neuroscience Board. Other previous national contributions include serving as the medical expert on the Independent Inquiry into the Misuse of Drugs Act (2000 Runciman report), and membership of the Committee on Safety of Medicines, the Committee on NHS drugs and the Ministry of Defence Science Advisory Board. He was the clinical scientific lead on the 2004/5 UK Government Foresight initiative "Brain science, addiction and drugs" that provided a 25-year vision for this area of science and public policy.

David broadcasts widely to the general public both on radio and television including BBC science and public affairs programmes on therapeutic as well as illicit drugs, their harms and their classification. He also lecturers widely to the public as well as to the scientific and medical communities; he has presented three time at the Cheltenham Science Festival and several times for Cafe Scientifi